KKR, a global investment firm, completed the acquisition of Biosynth Carbosynth, a life sciences reagents and custom synthesis and manufacturing services company, from Armira, a Munich-based holding group. Financial terms were not disclosed. "I would like to thank Armira for our trusting and very successful partnership over the last seven years. I am excited to welcome KKR as our strategic partner as they have the industry experience, international network, and resources to help us realize our vision of becoming a global platform. KKR’s strategic partnership will enable us to continue to scale the business while retaining the best-in-class product quality, science-led focus, and industry-leading expertise for which our customers have come to know us," Urs Spitz, Biosynth Carbosynth CEO and President.